Hormone replacement therapy (HRT) has long sat at the centre of a persistent medical debate, especially when it comes to women’s brain health in later life.

For decades, researchers, clinicians, and patients have questioned whether hormone therapy used to manage menopause symptoms might alter a woman’s risk of developing dementia.

A large new review published in The Lancet now brings a measure of clarity to that discussion. According to the findings, menopausal hormone therapy neither raises nor lowers the risk of dementia in post-menopausal women.

The results arrive at a time when interest in women’s cognitive ageing is growing, driven by the stark reality that dementia affects women more than men.

Around two-thirds of people living with dementia worldwide are women. While longer life expectancy explains part of this imbalance, it does not account for it fully. Biological, hormonal, and social factors are all believed to play a role, yet many of these areas remain underexplored.

The new analysis draws on data from ten previously published studies, covering more than one million women. By pooling results across such a large population, the researchers aimed to clarify whether hormone replacement therapy, often referred to as HRT or menopausal hormone therapy, has any measurable impact on dementia risk.

Their conclusion was clear. There was no convincing evidence that hormone therapy increased the likelihood of dementia. Equally, there was no evidence that it offered protection against cognitive decline or dementia later in life.

This finding challenges lingering concerns that hormone therapy might harm the ageing brain. It also tempers hope that hormones could be used as a preventive tool against dementia. For clinicians and patients navigating menopause, the message is pragmatic.

Hormone therapy decisions should be guided by symptom relief and established health considerations, not by expectations around dementia prevention.

The biological theory linking menopause to brain health has long been compelling. Oestrogen plays a role in brain function, influencing memory, mood, and neural connectivity.

During menopause, oestrogen levels fall sharply. Some scientists have suggested that this hormonal shift could contribute to changes in the brain that increase vulnerability to cognitive decline. Hormone therapy, in theory, might counteract some of these effects. Yet translating biological plausibility into real-world outcomes has proved difficult.

Over the years, studies examining hormone therapy and dementia risk have produced conflicting results. Some observational research hinted at an increased risk, particularly when therapy was started later in life. Other studies suggested possible cognitive benefits when treatment began earlier, around the time of menopause. These mixed messages created confusion for women and clinicians alike.

The new review sought to cut through that uncertainty by examining the totality of available evidence. The researchers also explored whether factors such as the age at which hormone therapy was started, the duration of use, or the type of hormones prescribed made any difference to dementia outcomes.

Once again, the data offered no clear answers. There was insufficient high-quality evidence to draw firm conclusions about timing, length of treatment, or formulation.

This limitation highlights a recurring problem in women’s health research. Much of the evidence comes from observational studies rather than long-term randomised controlled trials.

Observational studies can identify associations, but they struggle to prove cause and effect. Lifestyle, education, socioeconomic status, and underlying health conditions can all influence both hormone use and dementia risk, making results harder to interpret.

The researchers behind the review were open about these shortcomings. They described the certainty of the evidence as low and called for more rigorous research. Large, long-term trials involving diverse groups of women are needed to better understand how menopause, hormones, and brain health interact across the lifespan.

Despite these limitations, the findings carry real-world significance. In late 2025, the United States Food and Drug Administration announced the removal of so-called “black box” warnings on hormone therapy labels, including warnings related to dementia risk. This decision reflected a broader re-evaluation of the evidence surrounding hormone therapy, particularly when used appropriately in younger, recently menopausal women.

The latest review adds weight to the view that hormone therapy, when prescribed for menopausal symptoms, does not appear to harm cognitive health. For many women, menopause brings disruptive symptoms such as hot flushes, night sweats, sleep disturbance, mood changes, and brain fog. Hormone therapy remains one of the most effective treatments for these issues. Knowing that it does not appear to increase dementia risk may offer reassurance.

However, we have to caution that a meta-analysis summarises existing studies rather than generating new data. As such, it cannot resolve unanswered questions on its own. What it can do is confirm that, based on current evidence, there is no strong signal of either benefit or harm regarding dementia risk.

From a clinical perspective, this aligns with current practice. Hormone therapy is not recommended as a strategy to prevent dementia. Instead, it is prescribed to improve quality of life during menopause, taking into account age, medical history, and individual risk factors. The new findings reinforce this approach.

Age remains the strongest risk factor for dementia. As populations live longer, the number of people affected by cognitive decline continues to rise. At present, there are no proven interventions that reliably prevent dementia. Lifestyle measures, such as physical activity, cognitive engagement, social connection, and cardiovascular health management, are widely promoted, but their effects are modest and not guaranteed.

Some clinicians point out that hormone therapy can improve short-term cognitive symptoms often described as “brain fog” during menopause. Many women report clearer thinking, better concentration, and improved memory while on treatment. Whether these short-term benefits translate into long-term protection against neurodegenerative disease remains unknown.

Research into dementia prevention is increasingly focused on the underlying biology of diseases such as Alzheimer’s. One major area of interest involves amyloid proteins, which accumulate in the brains of people with Alzheimer’s disease. Efforts to develop treatments that reduce or clear these deposits are ongoing, though progress has been slow and controversial.

Against this backdrop, the hormone therapy debate reflects a broader issue in women’s health. Historically, midlife women have been under-represented in medical research. Menopause, despite being a universal experience, has often been treated as a niche topic rather than a major public health issue. This has left gaps in evidence and guidance, particularly in areas such as cognitive ageing.

International health bodies have yet to issue clear recommendations on hormone therapy and cognitive outcomes. The World Health Organization, for example, currently offers no specific guidance linking menopausal hormone therapy to dementia risk. Researchers hope that comprehensive reviews like this one will help inform future guidelines and policy decisions.

The authors of the study have indicated that their work is part of a broader effort to understand how the menopause transition affects the brain. This includes not only cognition, but also mental health and overall wellbeing. Factors such as stress, sleep, work demands, and cultural attitudes towards ageing and menopause may all shape cognitive experiences during midlife and beyond.

For women seeking clear answers, the message may feel unsatisfying. There is no simple intervention that guarantees protection from dementia. Hormone therapy is neither a villain nor a miracle cure in this context. It is a medical treatment with well-established benefits and risks that should be considered on an individual basis.

The study also serves as a reminder of the need for better research infrastructure. Long-term studies are expensive and complex, yet they are essential for understanding conditions that develop over decades. Including women from different backgrounds, ethnicities, and health profiles will be critical if future findings are to be widely applicable.

In the meantime, clinicians are encouraged to continue following evidence-based guidelines. Hormone therapy can be life-changing for women with severe menopausal symptoms. Concerns about dementia should not automatically deter its use, nor should hopes of cognitive protection drive treatment decisions.

For the public, the findings underscore the importance of realistic expectations. Dementia is a complex group of conditions influenced by genetics, ageing, health, and environment. No single therapy is likely to offer a simple solution. Progress will come through sustained research, prevention strategies across the lifespan, and improved care for those already affected.

As interest in women’s brain health grows, studies like this help refine the conversation. They replace fear and speculation with evidence, even when that evidence points to neutrality rather than dramatic effect.

In medicine, clarity often comes not from discovering a new benefit or risk, but from understanding where one does not exist.